Symbols

AQST

Aquestive·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

EPS Beats Expectation

FDA Approved

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AQST

Aquestive Therapeutics, Inc.

A company that developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies

Industry

Pharmaceutical

Established Date

Listing Date

07/25/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

147

Fiscal Year Ends

12-31

Website

aquestive.com

Security Type

Common stock

Office address

30 Technology Drive, Warren, NJ 07059

Business

Introduction

Aquestive Therapeutics, Inc., was incorporated in Delaware in January 2004. The company is a pharmaceutical company that advances medicines through innovative delivery technologies, focusing on developing alternatives to invasive standard therapies. It develops proprietary drug candidates including epinephrine prodrugs for anaphylactic shock and has licensed commercialized products manufactured by its factories.

Company Financials

EPS

AQST has released its 2025 Q4 earnings. EPS was reported at -0.26, versus the expected -0.13, missing expectations. The chart below visualizes how AQST has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AQST has released its 2025 Q4 earnings report, with revenue of 13.02M, reflecting a YoY change of 9.67%, and net profit of -31.86M, showing a YoY change of -86.81%. The Sankey diagram below clearly presents AQST's revenue sources and cost distribution.